Investor Presentaiton

IBI-310 (CTLA-4) Development Plan Overview Melanoma subtypes Part A (1a): IBI-310 N=10 Mucosal Acral 6 (60%) 5 (31.3%) Phase 1a/1b Safety Data (N=27) Part B+C (1b): IBI-310 + sintilimab N=17 IBI-310 + Sintilimab Development Program Overview . Melanoma Phase 3 trial in adjuvant setting (First patient dosed in China in Apr 2020) Cervical Clinical 3 (30%) 2 (12.5%) - Phase 2 trial in 2nd line and above Non-chronic sun damaged progress 1 (10%) 9 (56.3%) chronic sun damaged 0 1 (5.9%) Part A (1a): IBI-310 N=10 Part B+C (1b): IBI-310 + sintilimab N=17 HCC (First patient dosed in China in Dec 2020) Phase 3 trial in 1st line (First patient dosed in China in Feb 2021) DLT No DLT No DLT . Plan to complete patient enrolment for Cervical in 2021 AE > grade 3 No AEs of grade 3 One AE of grade 3: AST increased 2021 plan • Plan to present the Phase 1b study data of IBI-310 in HCC IBI-310 has shown good safety profile in Phase 1a/1b studies and progressed into registrational trials for multiple indications. Disclosed at ASCO 2020 Abstract Innovent Confidential Copyright©2021 Innovent Biologics 20 20

View entire presentation